GSK Points to ‘Macro Factors’ to Explain U.S. Shingrix Demand Crash

Shingrix sales in the U.S. took a 15% dive in the third quarter. GSK is now the second Big Pharma to report declining vaccine sales, after Sanofi reported a similar decline last week.